← Back to Search

Radiopharmaceutical

PET-MRI Heart Scan for Mitral Valve Regurgitation

Q: Is this experiment open for patient involvement at the present time?

<p>Affirmative. According to the clinicaltrials.gov page, this study is presently in search of 12 individuals from a single research centre. The trial first appeared on June 18th 2025 and was most recently updated on 9/6/2022.</p>

Q: How many participants are availing themselves of this medical research endeavor?

<p>Affirmative. Clinicaltrials.gov has records of this medical trial being actively advertised with the initial posting on June 18th, 2025 and the most recent update occurring on June 9th 2022. They are seeking 12 participants for their single site research centre.</p>

Phase < 1

Waitlist Available

Led By Pradeep Bhambhvani, MD

Research Sponsored by University of Alabama at Birmingham

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

At least 18 years of age

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 0-48 hours

Awards & highlights

Study Summary

This trial is looking at changes in the heart of people with a particular heart condition, and comparing them to healthy controls. They will use PET and MRI scans to look at different aspects of the heart, and how well it is functioning.

Who is the study for?

This study is for adults with chronic, asymptomatic primary mitral regurgitation (PMR) or healthy controls without heart conditions. Participants must be able to lie still for imaging and not exceed the PET table weight limit. Pregnant individuals, those unable to consent, with metal implants unsuitable for MRI, or significant comorbidities like heart failure or severe kidney disease cannot join.Check my eligibility

What is being tested?

[11C] acetate PET tracer is being tested to measure myocardial oxygen consumption in patients with PMR. Alongside this, cardiac MRI using a gadolinium-based contrast will assess myocardial inflammation and extracellular volume changes. The trial aims to enroll 12 participants for these non-invasive imaging studies.See study design

What are the potential side effects?

Potential side effects may include reactions related to the [11C] acetate PET tracer and gadolinium-based contrast agent used during MRI scans such as nausea, headache, dizziness, or allergic reactions. However, serious side effects are rare.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 0-48 hours

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~0-48 hours

This trial's timeline: 3 weeks for screening, Varies for treatment, and 0-48 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Quantitatively correlate metabolic findings from the PET component with quantitative T1 and T2 parametric mapping from the cardiac MR component of the hybrid PET-MR study.

Trial Design

2Treatment groups

Active Control

Group I: chronic compensated moderate-severe primary mitral regurgitation (PMR)Active Control1 Intervention

Group II: Healthy VolunteersActive Control1 Intervention

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor

1,589 Previous Clinical Trials

2,280,342 Total Patients Enrolled

Pradeep Bhambhvani, MDPrincipal InvestigatorUniversity of Alabama at Birmingham

Media Library

[11C] acetate (Radiopharmaceutical) Clinical Trial Eligibility Overview. Trial Name: NCT04795856 — Phase < 1

Mitral Valve Regurgitation Research Study Groups: chronic compensated moderate-severe primary mitral regurgitation (PMR), Healthy Volunteers

Mitral Valve Regurgitation Clinical Trial 2023: [11C] acetate Highlights & Side Effects. Trial Name: NCT04795856 — Phase < 1

[11C] acetate (Radiopharmaceutical) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04795856 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this experiment open for patient involvement at the present time?

"Affirmative. According to the clinicaltrials.gov page, this study is presently in search of 12 individuals from a single research centre. The trial first appeared on June 18th 2025 and was most recently updated on 9/6/2022."

Answered by AI

How many participants are availing themselves of this medical research endeavor?

"Affirmative. Clinicaltrials.gov has records of this medical trial being actively advertised with the initial posting on June 18th, 2025 and the most recent update occurring on June 9th 2022. They are seeking 12 participants for their single site research centre."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Understanding the Metabolic and Functional Derangement of Primary Mitral Regurgitation: a Feasibility Study Using Carbon 11(C-11) Acetate Cardiac Positron Emission Tomography Magnetic Resonance Imaging (PET-MRI)

Pradeep Bhambhvani, MD 2027. "Understanding the Metabolic and Functional Derangement of Primary Mitral Regurgitation: a Feasibility Study Using Carbon 11(C-11) Acetate Cardiac Positron Emission Tomography Magnetic Resonance Imaging (PET-MRI)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04795856.